EMERYVILLE, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today announced that Ron Najafi, Ph.D., Chairman and CEO of NovaBay Pharmaceuticals, will present a corporate and clinical update at the 8th Annual JMP Securities Healthcare Conference, held July 9-10, 2013 in New York City. Ron Najafi and Tom Paulson, Chief Financial Officer of NovaBay, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
| Event: | JMP Securities Healthcare Conference |
| Date: | Wednesday, July 10, 2013 |
| Time: | 4:00 pm EDT |
| Place: | New York City |
To access the live audio webcast of this presentation, please log on through a link located in the News & Events section of NovaBay's website at http://novabay.com/investors/events. A replay of the webcast will be available one hour after the conclusion of the live event.
About NovaBay Pharmaceuticals, Inc.
Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market with auriclosene. The Company's four core business units – DermaBay, UroBay, EyeBay and MediBay – are developing products in dermatology, urology, ophthalmology, and wound care areas.
| Stay informed on NovaBay's progress: |
| Like us on Facebook |
| Follow us on Twitter |
| Connect with NovaBay on LinkedIn |
| Join us on Google+ |
| Visit NovaBay's Website |